Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy
- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN
918864)
AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Research
at Helix BioPharma Corp., a developer of novel cancer therapeutics,
will be presenting a scientific poster at the Fourth International
Conference on Tumor Microenvironment, which runs from March 6th to
10th in Florence, Italy.
The conference, hosted by the International Cancer Microenvironment
Society, is a premier gathering of international cancer researchers
who seek to develop cancer therapies targeting microenvironmental
factors that control tumor growth and metastasis.
The poster, titled "L-DOS47 - a tumor microenvironment alkalization
agent and a novel lung adenocarcinoma specific therapeutic
candidate," provides a summary of selected L-DOS47 previously
announced findings. Included in the poster are laboratory data
showing the ability of L-DOS47 to bind to and destroy lung cancer
cells alone and synergistically with selected chemotherapeutic
drugs. Also being presented are mass tissue sample screening data,
which show that L-DOS47 binds not only to primary lung
adenocarcinoma tissues preferentially over a host of other
cancerous or normal tissues, but also to metastasized cells in
lymph nodes. The poster also highlights the ability of L-DOS47 to
localize and concentrate in tumor tissues specifically following
injection into laboratory animals
A copy of the poster will be available on Helix's website for
download at http://www.helixbiopharma.com.
For additional information on the Tumor Microenvironment
conference, please visit http://cancermicroenvironment.tau.ac.il/meeting-2007.html
About L-DOS47
L-DOS47 combines Helix's proprietary DOS47 new drug candidate
with a highly specific single domain antibody, to form a potential
new targeted drug product for the treatment of adenocarcinoma of
the lung, the most common form of cancer in the world today.
L-DOS47 is thought to function by leveraging a
natural process in the body called the urea cycle, to produce an
anti-cancer effect. It is based upon a naturally occurring enzyme
called urease that essentially reverses the urea cycle by breaking
down urea into metabolites that include ammonia and hydroxyl ions.
By doing so at the site of cancerous tissues in the body, L-DOS47
is believed to modify the microenvironmental conditions of lung
cancer cells in a manner that leads to their death. Among these
theorized effects, L-DOS47 is believed to stimulate an increase in
the pH of the microenvironment surrounding the cancerous cells,
effectively reversing the acidic extra-cellular conditions that are
known to be necessary for cancer cell survival. As well, the local
production of ammonia at the site of cancerous tissues is thought
to readily diffuse into the cancer cells to exert a potent
cytotoxic effect by interfering with their critical metabolic
functions.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus, and its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma. Helix is listed on the TSX under the symbol "HBP".
The Toronto and Frankfurt Stock Exchanges have not reviewed and
do not accept responsibility for the adequacy or accuracy of the
content of this News Release. Helix disclaims responsibility for
information contained in the Tumor Microenvironment conference
website, and the reference to such website in this News Release
does not constitute an endorsement by Helix of that or any other
website. This News Release contains certain forward-looking
statements regarding potential cancer therapeutics under
development by the Company, and in particular, regarding L-DOS47.
Forward-looking statements can be identified by the use of
forward-looking terminology such as "potential", "is thought", "is
believed", "new", "will", "theorized", or variations thereon or
comparable terminology referring to future events or results.
Forward looking statements are statements about the future and are
inherently uncertain, and Helix's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of numerous factors,
including without limitation, uncertainty whether L-DOS47 will be
developed successfully as a drug or at all; uncertainty whether
DOS47 will be developed as a therapeutic for any other cancers;
research & development risks, including the risk that early
R&D results may not be repeated in later R&D; the risk of
technical obsolescence; the need for regulatory approvals, which
may not be obtained in a timely matter or at all; the need for
clinical trials, the occurrence and success of which cannot be
assured; intellectual property risks; marketing/manufacturing and
partnership/strategic alliance risks; the effect of competition;
Helix's need for additional future capital, which may not be
available in a timely manner or at all, as well as a description of
other risks and uncertainties affecting Helix and its business, as
contained in Helix's latest Annual Information Form and other
filings with the Canadian
Securities Regulatory Authorities at www.sedar.com, any of which could cause
actual results to vary materially from current results or Helix's
anticipated future results. Forward-looking statements are based on
the beliefs, opinions and expectations of Helix's management at the
time they are made, and Helix does not assume any obligation to
update any forward-looking statement should those beliefs, opinions
or expectations, or other circumstances change.
For further information: Investor Relations, Christina Bessant,
The Equicom
Group Inc., Tel: (416) 815-0700 ext. 269, (800) 385-5451, Fax:
(416) 815-0080,
Email: cbessant@equicomgroup.com;
Media Relations, Matthew Haines, Noonan
Russo, Tel: (212) 845-4235, Fax: (212) 845-4260, Email:
Matthew.Haines@eurorscg.com,
www.NoonanRusso.com
Clinical Trial Results Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
